Teknimed S.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Teknimed S.A. - overview
Established
1990
Location
-, -, France
Primary Industry
Biotechnology
About
Teknimed S. A. is a French company specializing in advanced biomaterials for orthopedic, spine, and sports applications, providing innovative solutions for surgical and rehabilitation needs. Founded in 1990 and headquartered in France, Teknimed S.
A. is focused on developing biomaterials for healthcare applications. The company was acquired in November 2021 by a consortium led by Essling Capital, aiming to enhance its growth and expand its market presence, particularly in North America. The company has successfully completed 2 deals to date, with the most recent deal occurring in November 2021.
Teknimed specializes in the production of advanced biomaterials, focusing primarily on orthopedic, spine, and sports applications. Their core product offerings include orthopedic cements, synthetic bone grafts, and specialized instrumentation designed for both surgical and rehabilitation needs. These products are engineered to provide effective solutions for bone-related surgeries and treatments, enhancing patient recovery and outcomes. Teknimed's client base encompasses hospitals, surgical centers, and orthopedic specialists across various geographical markets, including Europe, North America, and select regions in Asia.
By offering high-quality materials such as PMMA bone cements and resorbable polymers, Teknimed serves end-users ranging from healthcare professionals to patients requiring innovative biomaterial solutions. In the most recent fiscal year, Teknimed generated revenue of USD 19. 56 mn, with an EBITDA of USD 4. 39 mn for 2023.
Following its acquisition in November 2021, Teknimed plans to accelerate its organic growth and expand its geographic footprint in North America. The focus will be on developing and launching new products in the biomaterials sector, enhancing its offerings for orthopedic and surgical applications. The resources from the recent acquisition will support these growth initiatives, targeting specific market segments by strategically increasing its presence in the North American healthcare market.
Current Investors
Multicroissance, Essling Capital, Bourrelier Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Biomaterials, Biopolymer Materials
Website
www.teknimed.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Teknimed S.A. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | Teknimed S.A. | - | ||||||||
| Buyout | Completed | Teknimed S.A. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.